Repligen (RGEN) Set to Announce Quarterly Earnings on Wednesday

Repligen (NASDAQ:RGEN) is scheduled to release its earnings data before the market opens on Wednesday, May 1st. Analysts expect Repligen to post earnings of $0.29 per share for the quarter. Repligen has set its FY 2024 guidance at 1.420-1.490 EPS and its FY24 guidance at $1.42-1.49 EPS.Parties that wish to listen to the company’s conference call can do so using this link.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, hitting analysts’ consensus estimates of $0.33. The firm had revenue of $155.74 million during the quarter, compared to analysts’ expectations of $155.38 million. Repligen had a net margin of 6.51% and a return on equity of 5.00%. The company’s revenue for the quarter was down 16.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.68 earnings per share. On average, analysts expect Repligen to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Repligen Stock Performance

NASDAQ RGEN opened at $166.14 on Tuesday. The stock has a market cap of $9.28 billion, a PE ratio of 230.75, a P/E/G ratio of 5.46 and a beta of 1.02. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.75 and a current ratio of 7.02. The firm has a 50-day moving average of $183.37 and a 200-day moving average of $173.88. Repligen has a 52-week low of $110.45 and a 52-week high of $211.13.

Insider Buying and Selling at Repligen

In related news, COO James Bylund sold 4,373 shares of the company’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $198.08, for a total transaction of $866,203.84. Following the completion of the sale, the chief operating officer now directly owns 14,135 shares in the company, valued at approximately $2,799,860.80. The sale was disclosed in a filing with the SEC, which is available through this link. In other Repligen news, COO James Bylund sold 4,373 shares of the business’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $198.08, for a total transaction of $866,203.84. Following the completion of the transaction, the chief operating officer now owns 14,135 shares of the company’s stock, valued at $2,799,860.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Anthony Hunt sold 16,707 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the completion of the sale, the chief executive officer now owns 185,249 shares in the company, valued at $36,575,562.56. The disclosure for this sale can be found here. In the last quarter, insiders have sold 25,597 shares of company stock valued at $5,039,532. 1.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on RGEN. Stifel Nicolaus boosted their price objective on Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. KeyCorp upped their price objective on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Repligen has an average rating of “Moderate Buy” and an average price target of $196.70.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.